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Abstract 
Prolonged urinary obstruction can lead to renal dysfunction and irreversible injury.  The 
recovery of renal function following decompression is heavily dependent on the degree of 
renal injury. This suggests that treatments aimed at mitigating renal injury could improve the 
recovery of renal function following decompression.  Previous studies have shown that 
hydrogen sulfide (H2S), an endogenous gasotransmitter, can reduce the histopathological 
markers of renal injury following unilateral ureteral obstruction (UUO). However, the effects 
of H2S on renal function following decompression is unknown. Using the UUO and 
reimplantation (UUO-R) model, we demonstrate that H2S accelerates the recovery of renal 
function following decompression and mitigates renal injury. In vitro, H2S attenuates the 
transforming growth factor beta 1-mediated epithelial-mesenchymal transition pathway by 
increasing the expression of inhibitory Smad7 and angiotensin II type 2 receptor.  These data 
suggest that H2S could potentially be a novel therapeutic strategy to improve patient 
outcomes in urinary obstruction.  
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Chapter 1  
1 Introduction 
1.1 Obstructive uropathy: background and etiology 
Obstructive uropathy is characterized by abnormalities in the urinary tract that result in 
the blockage of urine flow. The prevalence and etiology of obstructive uropathy vary 
with age.  Obstructions in children are typically caused by congenital defects that arise 
during embryonic development, resulting in anatomical abnormalities that obstruct the 
urinary tract. Congenital obstructive uropathy is one of the leading causes of end stage 
renal disease (ESRD) in children and accounts for 16.5% of all pediatric renal 
transplantations in North America (Roth et al. 2002).  In the young and middle-aged 
adult, urinary obstructions are typically caused to obstructive calculi (kidney stones). 
Studies estimate that approximately 10-15% of Americans will develop obstructive 
stones in their lifetime, with 40% risk of recurrence at 5 years and 75% at 20 years 
(Spernat & Kourambas 2011). In the elderly, urinary tract obstructions are more common 
in males and are typically caused by benign prostatic hyperplasia or prostate cancer 
(Klahr 2000). Ureteral obstructions can be unilateral or bilateral, and can be classified 
based on degree (complete or partial obstruction) and duration (acute and chronic). In this 
review, we will focus on the outcomes, pathophysiology, and potential therapies for 
obstructive uropathy. 
 
1.2 Pathogenesis of obstructive uropathy 
Urinary tract obstruction is one of the many causes of acute kidney injury (AKI) and 
chronic kidney disease (CKD). A possible treatment for AKI is dialysis, a process which 
can take days to weeks. While the mortality rate of AKI is approximately 50%, death 
from CKD-related injury or the need for dialysis and renal transplantation is generally the 
ultimate outcome of CKD (Ucero et al. 2014).  AKI and CKD share similar pathogenesis, 
including cellular injury, cell death and inflammation. In addition, tubulointerstitial 
2 
 
fibrosis is often observed in CKD and can also be detected in severe cases of AKI. 
Chronic UUO can lead to irreversible renal injury and dysfunction (Ucero et al. 2014). 
 
1.2.1 Hemodynamics and functional changes 
Upon complete unilateral obstruction, an initial increase in renal blood flow into the 
obstructed kidney is observed. This is a result of prostaglandin and prostacyclin 
production due to medullary compression. After a few hours, and as the obstruction 
persists, renal blood flow decreases. This is caused by increased vascular resistance and 
production of vasoconstrictors such as angiotensin II (Ang II) and thromboxane A2. 
Together, these events lead to the decrease in glomerular filtration rate (GFR). 
Correspondingly, an initial increase in intratubular pressure is observed. While this rise is 
observed in the first few hours, intratubular pressure decreases to pre-obstructive values 
within the first 24 hours. The decline in pressure is caused by decreased GFR, decreased 
sodium reabsorption, and increased removal of tubular fluid through lymphatic drainage. 
Collectively, these actions decrease renal fluid volume (Klahr 2000). 
 
Obstruction can also cause functional changes in tubular cells. Initially, there is an 
increase in sodium reabsorption in the tubules to mediate renal fluid volume. However, as 
the obstruction persists, sodium wasting occurs due to tubular injury and defects in the 
sodium/potassium ATPase enzymes. This disrupts the lumen potential necessary for 
hydrogen and potassium excretion, and the retention of hydrogen results in renal tubular 
acidosis. Furthermore, this prevents the distal nephrons from concentrating urine, which 
contributes to diuresis and inability to acidify urine upon relief of obstruction (Klahr 
2000).  
 
In chronic obstructive uropathy, the reduction of renal blood flow is maintained, which 
places the kidney in a state of ischemia. Consequently, reactive oxygen species (ROS) 
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that are harmful to renal tubular cells are generated, resulting in tubular injury and 
activation of the renin-angiotensin system (RAS). The subsequent increase in Ang II 
recruits inflammatory cells to the site of injury, ultimately leading to cell death and the 
release of transforming growth factor beta 1 (TGF-β1) (Klahr 2000).   
 
1.2.2 Tubular injury and cell death 
Tubular cell death occurs via apoptosis or necrosis and is a result of the mechanical and 
oxidative stress associated with ureteral obstruction. Apoptosis (cell suicide) is the main 
form of cell death observed in urinary obstruction and CKD (Ucero et al. 2014), and is 
characterized by chromosome condensation and cellular blebbing.  This form of cell 
death is regulated by increased expression of intracellular lethal molecules and 
downregulation of pro-survival mediators. A large variety of factors associated with 
obstruction, such as ischemia, hypoxia, Ang II, ROS, tumour necrosis factor α (TNF-α), 
and mechanical stretching, can lead to mitochondrial destabilization and release of 
cytochrome C. This ultimately stimulates the caspase-mediated apoptotic pathway and 
contributes to tubular cell loss (Truong et al. 2001). These apoptotic cells are 
subsequently removed by infiltrating macrophages and neighbouring native cells (Truong 
et al. 2001).  
 
Necrosis, on the other hand, is characterized by loss of cell membrane integrity and 
uncontrolled released of intracellular contents.  Lethal stimuli released due to tissue 
injury and oxidative stress cause necrotic cell death, which results in the release of 
damage-associated molecular patterns (DAMPs) such as high-mobility group box 1. The 
release of DAMPs activates toll-like receptors, which recruits leukocytes to the site of 
injury and subsequently initiates tissue inflammation (Lech & Anders 2013). Though 
prominent in the early stages of pathogenesis and inflammation, necrosis is not frequently 
observed in chronic renal injury (Ucero et al. 2014). 
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1.2.3 Tissue inflammation 
Interstitial inflammation is an early response to obstructive uropathy, and is characterized 
by infiltration of leukocytes that are attracted to the cytokines, chemokines, and 
membrane adhesion molecules released by injured renal parenchymal and endothelial 
cells. Interstitial leukocyte population increases from 12 hours to up to 14 days post-
obstruction and consists predominantly of macrophages (Ucero et al. 2014). Macrophages 
can be classically activated (M1) to produce cytokines and chemokines that induce 
inflammation, tubular apoptosis, and fibrosis, or alternatively activated (M2) to attenuate 
inflammation. Classically activated macrophages generate ROS and TNF-α, which 
ultimately exacerbate the death of renal epithelial cells(Kluth et al. 2004). Additionally, 
interleukin (IL)-1β production can be observed. Together with TNF-α, IL-1β targets 
nuclear factor-κB (NF-κB) to increase the production of pro-inflammatory mediators 
such as monocyte chemoattractant protein-1 (MCP-1) and IL-1β (Sakurai et al. 1996), 
resulting in an amplified inflammatory response. M2 macrophages, on the other hand, 
appear in the later stages of inflammation. They play a critical role in the uptake of 
apoptotic cells and are known to suppress immune responses and induce tissue 
remodeling (Kluth et al. 2004). These macrophages release IL-4, IL-13, IL-10 and TGF-
β1 to reduce tissue inflammation and induce tissue repair. Importantly, TGF-β1 plays a 
crucial role in the induction of fibrosis, which leads to tissue scarring and loss of function 
(Lech & Anders 2013). 
 
1.2.4 Tubulointerstitial fibrosis 
As chronicity of inflammation associated with obstructive uropathy persists, fibrosis 
characteristic of CKD can eventually be observed. This is characterized by activation of 
fibroblasts that deposit extracellular matrix (ECM) components, such as fibronectin, 
collagen type I and III into the interstitial space(Eddy et al. 2012). These fibroblasts can 
be a result of resident fibroblasts proliferation or derived from tubular epithelial cells 
undergoing epithelial-mesenchymal transition (EMT) (Samarakoon et al. 2012). TGF-β1 
is a profibrotic cytokine released during inflammation and plays a critical role in 
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initiating the EMT response. Upon stimulation with TGF-β1, Smad 2 and Smad 3 protein 
are phosphorylated to induce fibrosis, while Smad 7, an in inhibitor of the fibrotic 
pathway, is degraded via ubiquitination. Under these circumstances, renal epithelial cells 
lose their adhesions to neighbouring cells and basement membrane, increase expression 
of mesenchymal proteins such as vimentin, decrease expression of epithelial proteins 
such as E-cadherin, and migrate into the interstitium (Ucero et al. 2014; Chevalier 2006). 
Propagation of tubulointerstitial fibrosis is commonly observed in CKD and can lead to 
irreversible renal injury and loss of renal function (Iwano & Neilson 2004).   
 
Due to its ability to stimulate TGF-β1, Ang II is also a key mediator in the initiation of 
renal fibrosis. Previous studies have demonstrated that administration of enalapril, an 
angiotensin-converting enzyme (ACE) inhibitor, leads to decreased production of TGF-
β1 mRNA (Kaneto et al. 1993), and treatment with lorsartan, an angiotensin AT1 
receptor inhibitor, attenuated the progression of renal fibrosis (Manucha et al. 2004).  
Additionally, the synthesis of active TGF-β1 requires the conversion of latent 
preproTGF-β1 to the biologically active form of TGF-β1, a process that is promoted by 
RAS (Gibbons et al. 1992). Taken together, these studies suggest that Ang II plays a 
critical role in the initiation of renal fibrosis through stimulation of TGF-β1 production.  
The increase in TGF-β1 leads to the induction of EMT in renal epithelial cells and 
ultimately results in tubulointerstitial fibrosis characteristic of CKD (Xu et al. 2009).  
 
In addition, Ang II contributes to fibrosis by indirectly increasing the proliferation of 
renal fibroblasts. Ang II produced as a result of ureteral obstruction causes 
vasoconstriction and therefore local ischemia and hypoxia. Tubular cells subsequently 
undergo atrophy and cell death due to restricted blood flow, reduced nutrients, and 
depleted oxygen supply. The remaining cells undergo hypermetabolism, resulting in 
increased oxygen consumption and ultimately, perpetuation and exacerbation of hypoxia 
in the interstitium. This causes fibroblasts to proliferate and induce ECM production by 
epithelial cells (Iwano & Neilson 2004). Furthermore, Ang II stimulates TNF-α 
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production, which increases the formation of superoxide anions and perpetuates 
inflammation, thereby indirectly exacerbating the progression of fibrosis (Iwano & 
Neilson 2004).  
 
1.3 Recovery upon the relief of ureteral obstruction 
While surgical removal of obstruction removes the source of injury, recovery of renal 
function is dependent on the duration of the obstruction and renal function may not return 
back to pre-obstructive state (Vaughan JR. & Gillenwater 1971). Studies demonstrate that 
relief of obstruction was not able to recover the 40% loss of nephrons and did not 
improve tubular proliferation (Chevalier et al. 1999). In addition, relief of obstruction 
was not able to fully return TGF-β1 and vimentin expression to normal levels, suggesting 
that tubular injury continues to persist (Chevalier et al. 1999).  Similarly, Chaabane et al. 
observed a 40% reduction in GFR and a 50% reduction of glomerulotubular integrity 
after a 30-day recovery following a 7-day obstruction (Chaabane et al. 2013). 
Furthermore, albuminuria was also observed, implicating residual glomerular injury 
(Chaabane et al. 2013). Therefore, while relief of obstruction attenuates renal injury, 
complete reversal is unlikely and residual injury in the post-obstructed kidney may lead 
to renal dysfunction in later life. Thus, prevention of renal injury during obstruction may 
be a potential treatment option to improve post-obstructive renal function (Chevalier et 
al. 1999). 
 
1.4 Animal models of obstructive uropathy 
One of the most widely used experimental models of renal injury and urinary obstruction 
is the unilateral ureteral obstruction (UUO) model. Male animals are typically used in this 
experimental model, as female sex organs increase the technical difficulty of the 
procedure. After placing the animal under general anesthesia, a midline incision is made 
in the abdomen and the left ureter is found. Two sutures, one proximal and one distal to 
the kidney, are made in the ureter to permanently ligate the ureter. This procedure inflicts 
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renal injury upon the obstructed kidney while allowing the contralateral kidney to 
compensate for the unilateral loss of function (Ucero et al. 2014).  There are several 
advantages of this model: it is a relatively simple procedure, it does not involve the use of 
an exogenous toxin, and it does not create a uremic environment (Chevalier et al. 2009). 
Additionally, this model can be used to explore both acute and chronic renal injury, as the 
initial insult can result in AKI and persistence of obstruction can produce histological 
indices of CKD, particularly fibrosis, after a few weeks (Ucero et al. 2014). While renal 
injury in the UUO model can be histologically evaluated, functional changes of the 
obstructed kidney cannot be determined as the contralateral kidney compensates for the 
loss of renal function. Tapmeier et al. developed the unilateral ureteral obstruction and 
reimplantation (UUO-R) model, in which the obstructed ureter is reimplanted into the 
bladder, thus emulating relief of obstruction. The contralateral kidney is subsequently 
removed, which causes the animal to depend solely on the previously obstructed kidney 
and allows for both histological and functional evaluation of the obstructed kidney 
(Tapmeier et al. 2008).  
 
1.5 Pharmacological interventions in obstruction 
To complement surgical relief of obstruction, pharmacological treatments may be used to 
prevent the recurrence of stones, treat existing stones, or manage symptoms associated 
with obstruction. Diuretics, such as thiazide diuretics and indapamide, can decrease 
calcium excretion and therefore reduce the risk of calcium stone formation. While 
beneficial, these drugs may cause hypocitriuria, hypokalemia, hyponatremia, dizziness, 
weakness, and gastrointestinal upset (York et al. 2015). Potassium citrate and sodium 
citrate are two common urinary alkalinizers used to prevent crystallization, however, like 
diuretics, they may also cause gastrointestinal distress. Additionally, a common side 
effect of potassium-containing therapeutics is hyperkalemia, which can potentially be 
dangerous in patients with renal failure (York et al. 2015). To treat uric acid stones, 
xanthine oxidase inhibitors are often used as they decrease urinary acid excretion, 
however they are often associated with hepatotoxicity, skin rashes, and gastrointestinal 
distress (York et al. 2015). Due to poor intestinal or renal tubular transport of cystine, 
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high urinary cystine levels may cause cystine stone formation. As such, Tiopronin and D-
penicillamine are typically used to form disulfides to decrease cystine excretion and 
reduce the risk of cystine stone formation (York et al. 2015). Furthermore, severe flank 
pain is a common symptom among patients with urinary obstruction. As a result, 
acetaminophen, cyclooxygenase-inhibitors, non-steroidal anti-inflammatory drugs 
(NSAID) and opioids are typically prescribed to mediate pain. However, these drugs can 
have mild to severe side effects, including gastrointestinal distress, hepatotoxicity, 
respiratory depression, and addiction (York et al. 2015). Several pharmacological 
interventions are available to induce the expulsion of urinary stones. For instance, alpha-
blockers may improve the expulsion of urinary stones by inducing ureter relaxation, 
however, these drugs may cause nausea and nasal congestion (York et al. 2015). While 
effective, these drugs are not able to mitigate the accumulation of renal injury during 
obstruction. If prolonged, obstruction can cause irreversible renal injury and lead to 
permanent loss of renal function (Kerr JR 1956). Furthermore, studies have shown that 
relief of obstruction can only mitigate, but not reverse, renal injury (Wu et al. 2012). 
Therefore, preemptive therapies administered during the course of obstruction may help 
improve renal function following the relief of obstruction.  
 
1.6 Endogenous gasotransmitters and their potential roles 
in the treatment of obstruction  
Recent evidence suggests that gasotransmitters can exhibit anti-inflammatory and anti-
oxidant effects in various models of tissue injury (Wang 2002).  Gasotransmitters are 
small, endogenously produced gaseous molecules that have specific cellular and 
molecular targets, can freely permeate membranes, and have physiological functions 
(Qian & Matson 2016). Currently, nitric oxide (NO), carbon monoxide (CO), and 
hydrogen sulfide (H2S) are identified as gasotransmitters.   
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1.6.1 Nitric oxide  
NO is produced endogenously by nitric oxide synthases (NOSs), a family of enzymes 
including inducible NOS (iNOS), neuronal NOS (nNOS) and endothelial NOS (eNOS), 
from L-arginine. Classically, NO acts by activating soluble guanylate cyclase (sGC) to 
increase the production of 3’,5’-cyclic guanosine monophosphate (cGMP), ultimately 
leading to the activation of protein kinases and mediate various physiological responses 
(Qian & Matson 2016). For instance, in the circulatory system, NO can induce smooth 
muscle cell relaxation to cause vasodilation, thus making it an excellent therapeutic 
option for hypertension and related cardiovascular diseases (Qian & Matson 2016). In 
inflammatory processes, NO can act as a ‘double-edged sword’ depending on its 
concentration. Pro-inflammatory cytokines can cause an upregulation of iNOS in 
macrophages and neutrophils and lead to an excessive production of NO (Sharma et al. 
2007). Consequently, more phagocytes are recruited to the site of inflammation and 
through positive feedback, generate supra-physiological concentrations of NO, which can 
lead to sepsis (Kumar et al. 2017). However, at low concentrations, NO plays an anti-
inflammatory role by reducing the expression of endothelial cell adhesion molecules and 
thus mitigate inflammation by inhibiting leukocyte adhesion to the endothelium (Lefer & 
Lefer 1999).  Furthermore, studies have shown that treatment with L-arginine ameliorates 
renal fibrosis, apoptosis, and inflammation following UUO, which suggests that NO may 
serve as a potential therapy against damages associated with urinary obstruction (Sun et 
al. 2012).   
 
1.6.2 Carbon monoxide  
Heme oxygenases (HO), both inducible and constitutive, convert heme into iron, 
biliverdin, and CO. Interestingly, the production of NO and CO are closely related: CO 
can bind to NOS to increase NO production and NO can activate inducible HO to 
stimulate CO production. Like NO, CO can also diffuse through cell membranes and bind 
to sGC to increase cGMP production and cause smooth muscle relaxation (Gibbons & 
Farrugia 2004). Though toxic at high concentrations, CO can be therapeutic at low doses. 
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For instance, like NO, CO also exhibits anti-inflammatory effects due to its ability to 
mitigate the production of pro-inflammatory cytokines and increase the production of 
anti-inflammatory mediators (Motterlini & Foresti 2013).  In renal ischemia reperfusion 
injury (IRI), CO has been shown to decrease oxidative stress, tubular apoptosis and 
inflammation (Abe T, Fujino M, Yazawa K, Imamura R, Hatayama N, Kakuta Y, 
Tsutahara K, Okumi M, Ichimaru N, Kaimori JY, Isaka Y, Seki K, Takahara S, Li X-K 
2017). Studies by Wang et al. have demonstrated that in low-dose treatment with CO in 
UUO leads to decreased renal fibrosis. CO can mitigate ECM deposition in vivo and 
attenuate the TGF-β1-mediated fibrosis pathway in vitro (Wang et al. 2008).  Through 
controlled inhalation or administration of CO-releasing molecules (CORM), CO can 
exhibit therapeutic effects in various models of tissue injury, as demonstrated in the lung, 
liver, intestine, and kidney (Bauer & Pannen 2009; Wallace et al. 2015; Qian & Matson 
2016). 
 
1.6.3 Hydrogen sulfide 
Along with NO and CO, H2S was recently identified as the third gasotransmitter. Using 
L-cysteine, H2S is endogenously produced by cystathionine β-synthase (CBS), 
cystathionine γ-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST); these 
enzymes are expressed in majority of human cell types, producing H2S in the nanomolar 
to micromolar range (Whiteman et al. 2011). By acting on KATP channels, H2S exerts 
physiological effects on the cardiovascular system by mediating smooth muscle cell 
relaxation and vasodilation (Wang 2002).  Additionally, H2S can mediate metabolism, 
scavenge ROS, mitigate apoptosis and reduce inflammation (Wang 2002; Lobb et al. 
2014). Due to its broad variety of function, disruption of H2S production has been 
implicated in diseases such as hypertension, cancer, CKD and diabetes (Whiteman et al. 
2011).  In the kidney, CSE, CBS and 3-MST are primarily found in the proximal tubules 
(Yamamoto et al. 2013). These enzymes play a major role in regulating renal 
hemodynamics by altering blood flow, GFR, and urine excretion due to its vasodilatory 
properties (Xia et al. 2006). In addition, H2S may play a role in regulating renin-
angiotensin system (RAS) via modulation of cAMP and ROS production (Xue et al. 
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2013). Due to its multifaceted effects on renal physiology, dysregulation of H2S 
production has been implicated in chronic kidney disease and other renal pathologies 
(Lobb et al. 2014). 
 
1.6.3.1 Hydrogen sulfide in ureteral obstruction  
In ureteral obstruction, H2S has been shown to mediate tubulointerstitial fibrosis, 
oxidative stress, and inflammation. Tubulointerstitial fibrosis has been associated with 
decreased expression of CBS and CSE, and therefore decreased H2S concentration (Jung 
et al. 2013). Interestingly, Jung et al. has demonstrated that exogenous treatment with 
sodium hydrogen sulfide (NaHS, a H2S producer) can mediate the decrease in CBS and 
CSE expression (Jung et al. 2013). Furthermore, after seven days of treatment, NaHS 
reduced fibrosis and mitigated the increase in TGF-β1, Smad3, and NF-κB expression, 
suggesting that the H2S production pathway may be a potential target for mediating 
fibrosis associated with ureteral obstruction (Jung et al. 2013).  
 
The induction of fibrosis is exacerbated by oxidative stress, as ROS have been reported to 
increase the expression Ang II and TGF-β1 (Song et al. 2015). Therefore, mitigating ROS 
production may potentially be a way to alleviate tubulointerstitial fibrosis. A study by 
Jiang et al. demonstrated that exogenous treatment with NaHS significantly alleviated 
oxidative stress associated with UUO after 10 days of treatment (Jiang et al. 2014).  
When compared to control, UUO animals treated with NaHS demonstrated decreased 
expression of malondialdehyde (MDA, a marker for increase lipid peroxidation 
associated with ROS accumulation) and increased expression of superoxide dismutase 
(SOD, a free radical-scavenging enzyme) (Jiang et al. 2014). Correspondingly, NaHS 
significantly attenuated fibrosis associated with UUO (Jiang et al. 2014). Therefore, due 
to its anti-oxidant properties, H2S may potentially reduce UUO-induced renal injury.  
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The anti-inflammatory properties of H2S are well-established (Szabó 2007). As 
previously discussed, inflammation plays a crucial role in the development and 
progression of fibrosis. A study by Song et al. demonstrated that, in a rat model of UUO,  
H2S treatment mitigated inflammation and attenuated fibrosis (Song et al. 2014).  After 
treating UUO animals with NaHS for 7 days, decreased infiltration of macrophages and 
reduced expression of IL-1β, TNF-α and MCP-1 mRNA were observed when compared 
to control animals (Song et al. 2014). Similarly to Jiang et al., Song et al. also observed 
that NaHS can alleviate fibrotic injury by attenuating TGF-β1 expression and fibroblast 
proliferation (Song et al. 2014).  
 
Collectively, these studies suggest that the ant-fibrotic effects of H2S may in part be 
mediated by its anti-oxidant and anti-inflammatory properties. Taken together, these 
findings suggest that exogenous H2S may be a potential therapy against renal injury 
associated with UUO.  
 
1.6.3.2 GYY4137, a slow-releasing hydrogen sulfide donor  
The use of H2S in literature have largely been limited to sulfide salts such as NaHS. 
These molecules release supra-physiological amounts of H2S instantaneously in solution, 
therefore unlikely to emulate the slow and sustained release of H2S in biological systems. 
GYY4137 is a novel water-soluble H2S donor that releases H2S over a sustained period of 
time (from hours to days) (Li et al. 2008). Studies have shown that exposing vascular 
smooth muscle cells to low concentrations of GYY4137 leads to sustained 
vasorelaxation, as opposed to the transient effects of NaHS (Li et al. 2008). To evaluate 
the effects of GYY4137 on inflammation, Li et al. evoked inflammation in mice by 
administering lipopolysaccharide. Upon treatment with GYY4137, they observed reduced 
macrophage infiltration, along with decreased expression of TNF-α and IL-1β, 
confirming that GYY4137 retains the anti-inflammatory properties of H2S (Li et al. 
2013).  Additionally, Lin et al. has recently demonstrated the anti-inflammatory and anti-
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fibrotic of GYY4137 in a rat model of chronic UUO. Mirroring the downregulation of 
EMT markers in renal tissue, administration of GYY4137 also attenuated the progression 
of EMT in vitro (Lin et al. 2016). Taken together, these studies conclude that GYY4137 
is a slow-releasing H2S donor molecule with anti-inflammatory, anti-apoptotic, anti-
oxidant, and anti-fibrotic properties and can exhibit protective effects in various models 
of tissue injury.  
 
1.6.3.3 Development of clinically viable hydrogen sulfide-releasing 
therapeutics  
Due to the promise that H2S holds, there has been a surge in research and development of 
clinically viable H2S-donors, such as garlic-derived compounds including allyl disulfide, 
and more recently, H2S-releasing drugs, such as sodium polysulthionate (SG-1002), 
Zofenopril and ATB-346 (Wallace et al. 2017). SG-1002 has been shown to restore 
plasma H2S and NO levels in patients with congenital heart failure, and has recently been 
approved for Phase 2 clinical trials (Wallace et al. 2017). Zofenopril is an ACE inhibitor 
prodrug that metabolizes to zofenoprilat, a sulfhydryl-containing metabolite. It exhibits 
cardioprotective and vasculoprotective properties, and due to its sulfhydryl moiety, also 
exhibits anti-oxidant effects (Wallace et al. 2017).  Though NSAIDs are commonly used 
to mediate pain and inflammation, they often carry the risk of gastrointestinal distress, 
bleeding, and ulceration. Antibe Therapeutics recently developed ATB-346, a naproxen-
based drug linked to an H2S-donor, with the aim of using the gastroprotective effects of 
H2S to help mediate the side effects associated with NSAIDs. ATB-346 has recently 
successfully completed Phase 2 clinical trials in patients with osteroarthritis (Wallace et 
al. 2017). 
 
1.7 Conclusions and future therapeutic implications  
Prolonged ureteral obstruction can lead to accumulation of renal damage, ultimately 
resulting in loss of renal function. While surgical relief of obstruction removes the source 
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of insult, renal function and renal injury may not be fully reversed, and this residual 
injury can lead to renal dysfunction in later life. H2S possesses several protective 
properties and has been shown to mitigate the accumulation of renal injury in chronic 
UUO. This suggests that, in the future, H2S-based therapeutics may potentially be used to 
improve post-obstructive renal function and clinical outcomes. Though still in the early 
stages of development, H2S-releasing drugs show considerable promise. If administered 
throughout the duration of UUO, H2S-releasing drugs may be a potential solution to 
attenuate renal damage and improve renal function following relief of urinary 
obstruction. 
 
1.8 Research aims and hypotheses  
While various groups have explored the effects of H2S on ureteral obstruction using the 
UUO model (Song et al. 2014; Jiang et al. 2013; Lin et al. 2016), a limitation of the UUO 
model lies in the fact that renal injury can only be determined histopathologically. 
However, the aim of a therapeutic intervention is to improve renal function. Thus, we 
propose to use the UUO-R model (Tapmeier et al. 2008) to evaluate the effects of H2S 
treatment on renal function following the relief of urinary obstruction. We will administer 
H2S donor GYY4137 during obstruction, as well as during obstruction and following 
decompression. We will then evaluate the functional response of the kidney following the 
relief of obstruction. Additionally, we intend to determine the mechanisms behind the 
anti-fibrotic properties of GYY4137 through in vitro assays.  
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Aim 1: To investigate the effects of GYY4137 on renal function following the relief of 
ureteral obstruction.  
Hypothesis: GYY4137 treatment will mitigate renal damage and improve renal function. 
 
Aim 2: To determine the mechanism by which GYY4137 mitigates fibrosis by 
employing an in vitro model of EMT using a rat kidney epithelial cell line (NRK52E).  
Hypothesis: GYY4137 will attenuate fibrosis by moderating the TGF-β1-mediated EMT 
pathway. 
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Chapter 2  
2 Materials and Methods 
2.1 Animal description and care 
Adult male Lewis rats (250-300g; Charles River Laboratories International Ltd.) were 
maintained in the Animal Care and Veterinary Services facility at Western University. 
Animals were managed in accordance with the guidelines set by Committee on Care and 
Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National 
Research Council. All experiments were approved by Council on Animal Care and 
Animal Use Subcommittee of Western University. In accordance to the “reduce-reuse-
recycle” philosophy established by the Animal Use Subcommittee, we used the fewest 
number of animals in our study to establish a biological and statistical significance.  
 
2.2 Optimizing and establishing a reversible unilateral 
ureteral obstruction model 
The UUO model is a widely accepted model used to mimic urinary obstruction and study 
renal injury(Kaneto et al. 1993). However, renal injury can only be determined through 
histopathological methods, and as the contralateral kidney remains intact, the UUO 
model cannot provide data regarding the function of the affected kidney post-obstruction. 
As such, we sought to employ a reversible UUO model to evaluate renal function post-
obstruction.  
 
2.2.1 Optimizing the duration of urinary obstruction 
The duration of urinary obstruction was optimized such that it inflicts sufficient renal 
injury while allowing for functional recovery post-obstruction. Male Lewis rats 
underwent UUO procedure(Kaneto et al. 1993). Briefly, rats anesthetized with ketamine 
(30 mg/kg) and maintained under anesthesia with 1% isofluorane. The left ureter was 
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ligated at the ureterovesical junction, as close to the bladder as possible. Rats were 
sacrificed on post-operative day (POD) 3, 7, and 14 (n=2 each), and the left kidney was 
removed for histological analysis with terminal deoxynucleotidyl-transferase-mediated 
dUTP nick end labeling (TUNEL) and Masson’s trichrome. A renal pathologist blind to 
the animals’ assignment groups evaluated the slides to determine the optimal duration of 
ligation and ideal severity of renal injury.  The optimal duration of obstruction was 
determined to be 14 days. 
 
2.2.2 Optimizing the surgical protocol of a reversible UUO model 
A reversible UUO surgical protocol was established to allow us to evaluate post-
obstructive renal function. We adapted the surgical procedure established by Chaabane et 
al. to a 14-day rat urinary obstruction model (Chaabane et al. 2013). Rats (n=2) were 
placed under general anesthesia. A catheter was placed adjacent to the left ureter, and the 
ureteral ligation was completed by suturing the ureter to the catheter. On POD14, the 
catheter was cut to release the ligation.  However, the integrity of the ureter was 
compromised, resulting in death due to urine leakage. To prevent urine leakage, we 
further modified this model by inserting a stent into the ureter after relief of obstruction 
on POD14. However, this was not a viable model as the stent injured the lumen of the 
ureter and caused ureteral bleeding. 
 
2.2.3 Unilateral ureteral obstruction and reimplantation (UUO-R) 
model and post-operative care 
The UUO-R model established by Tapmeier et al. was successfully modified to a 14-day 
model in rats(Tapmeier et al. 2008). Male Lewis rats were randomly divided into 4 
groups: Sham (n=5), UUO-R (n=10), UUO-R + 14 day GYY4137 (n=11), and UUO-R + 
30 day GYY4137 (n=5).  All animals were placed under general anesthesia. Sham 
animals underwent midline incision and closure, while all other animals underwent UUO 
procedure (the left ureter was directly ligated at the ureterovesical junction). The incision 
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was closed and animals were placed back into their cages. From POD 1 to 14, rats in 
UUO-R group received daily intraperitoneal (IP) injections of phosphate buffered saline 
(PBS, 1 mL, vehicle), while rats in the UUO-R + 14 day GYY4137 and UUO-R + 30 day 
GYY4137 received daily IP injections of GYY4137 (200 µmol/kg GYY4137 in 1 mL 
PBS).   
 
On POD 14, all rats were placed under anesthesia and a midline incision was made. Sham 
rats underwent right nephrectomy and closure. All other rats underwent the 
reimplantation procedure. Briefly, the obstructed ureter was freed of surrounding 
adhesions and the ligature was cut such that the ureter was unobstructed and urine flowed 
freely through the ureter lumen. An 18-gauge needle was pushed into the left side of 
bladder, into the cavity, and out through the right bladder wall. Using forceps to hold the 
sharp end of the needle, the needle and forceps were back pushed through the bladder and 
out the left side of the bladder. The distal end of the unobstructed ureter was grasped with 
forceps and pulled into the bladder cavity and out through the right bladder wall. Using 
10-0 silk sutures, 12 stitches were placed to secure the ureter to the left bladder wall. The 
distal end of the ureter was allowed to move back into the bladder, and the defect on the 
right bladder wall was closed with 10-0 silk sutures. A right nephrectomy was performed 
to allow animals to depend solely on the previously obstructed kidney. The midline 
incision was closed and the animals were returned to their cages. Rats in the UUO-R + 30 
day GYY4137 continued to receive daily IP injections of GYY4137 from POD 15 to 30. 
On PODs 3, 7, 10, 17, 21, 24, and 30, or until sacrifice, all animals were placed in 
metabolic cages for 24-hour to measure water intake and urine output. In addition, 200µL 
of blood was collected from tail vein and centrifuged at 10000xg for 10 minutes to obtain 
serum. Serum and urine samples were analyzed at London Health Science Centre 
(LHSC) Core Laboratory for serum creatinine and electrolytes and urine creatinine, 
protein, and electrolytes. Animals were sacrificed on POD 30. As two animals in the 
UUO-R group were euthanized prematurely on POD 18 due to renal failure, an subset of 
animals were sacrificed on POD 18 (UUO-R, n=3; UUO-R + 14 day GYY4137, n=5) for 
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analysis. The left kidney was removed at time of sacrificed and divided sagittally, with 
half used for either histological or RNA and protein analysis.  
 
 
Figure 1. Unilateral ureteral obstruction and reimplantation model in rats.   
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2.3 Histopathological evaluation 
2.3.1 Histology 
Tissues were stored in 10% formalin, embedded in paraffin and sectioned. Subsequently, 
sections were stained with hematoxylin and eosin (H&E). Sections were also stained with 
TUNEL (Genetex) to quantify the number of apoptotic cells and Masson’s trichrome 
(Abcam) to determine the degree of fibrosis.  
 
2.3.2 Immunohistochemistry 
Macrophage and neutrophil infiltration were determined via immunohistochemistry 
(IHC) with antibodies against CD68 (Abcam) and myeloperoxidase (MPO, Abcam), 
respectively. IHC sections were visualized using the Dako Envision System with 
secondary antibodies and DAB substrate chromogen as per manufacturer’s protocol. 
 
2.3.3 Immunofluorescence 
Quantification of M1 and M2 macrophages was determined through immunofluorescence 
(IF). Slides were incubated with antibodies against CD68 and CD206 (Abcam), followed 
by AlexaFluor 405-conjugated and AlexaFluor 488-conjugated secondary antibodies, as 
per manufacturer’s protocol.  
 
2.3.4 Image analysis 
Whole-slide scans of H&E sections were taken with ScanScope AT Turbo Aperio (Leica 
Biosystems) and cortical thickness was measured by a blinded renal pathologist.  TUNEL, 
Masson’s trichrome, and IHC (CD68 and MPO) sections were imaged using Nikon 
Eclipse 90i light microscope at 10x magnification at 5 random areas. Image J software 
(National Institute of Health) was used to quantify the number of positive cells or 
positively stained areas of fibrosis. IF samples were viewed with FLUOVIEW X831 
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confocal microscope (Olympus) at 40x magnification. Images were acquired with 
FLUOVIEW FV10 ASW4.0 viewer.  Number of CD68+ (blue), CD206+ (green), and 
CD68+/ CD206+ (cyan, overlay of blue and green) cells were quantified using Image J 
software.  
 
2.4 Measurement of urinary H2S levels 
MeRho-Az (Sonke et al. 2015; Hammers et al. 2015), an H2S-specific fluorescent probe, 
was used to determine if daily IP injection of 200 µmol/kg GYY4137 increased urinary 
levels of H2S. MeRho-Az was generously donated by Dr. Michael Pluth (University of 
Oregon, Eugene, OR). Male Lewis rats were divided into two groups, UUO (n=5) and 
UUO + GYY4137 (n=5), and all animals underwent UUO procedure as described above. 
From POD 1 to POD 3, rats in the UUO group received daily IP injections of PBS (1 mL) 
while animals in the UUO + GYY4137 group received daily IP injections of GYY4137 
(200 µmol/kg GYY4137 in 1 mL PBS). At sacrifice (POD 3), 25-gauge needle was 
inserted into the obstructed ureter to collect urine. Immediately, 20µM of MeRho-Az was 
added to urine and samples were flash frozen with liquid nitrogen and stored in -80oC. To 
determine the concentration of H2S in urine, a standard curve was made with sodium 
sulfide (Na2S•9H2O) in 20µM of MeRho-Az. Standards and urine samples were pipetted 
into 96-well plates. Fluorescence intensity of samples was quantified using a fluorescent 
plate reader (Synergy H4 Hybrid Reader, BioTek) at λexcitation = 476 nm and λemission = 516 
nm. 
 
2.5 Cell culture and treatment 
NRK52E cells (ATCC) were seeded in 6 well plates at 1.5 x 105 cells/well with 
Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Fisher Scientific) supplemented 
with 5% fetal bovine serum (FBS) and 1% penicillin and streptomycin at 37oC under 5% 
CO2.  At 90% confluency, cells were serum starved with basic DMEM for 24 hours. 
Subsequently, cells were either treated with 10ng/mL TGF-β1 (Peprotech), 10 µM 
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GYY4137, 50 µM GYY4137, 10 ng/mL TGF-β1+10 µM GYY4137, 10 ng/mL TGF-
β1+50 µM GYY4137 or untreated in serum-free DMEM for 48 hours.  
 
2.6 Western blot 
Protein from NRK52E cells was collected using RIPA lysis buffer (Thermo Fisher 
Scientific) as per manufacturer’s protocol and quantified using NanoDrop 1000 
Spectrophotometer (Thermo Scientific). 50 µg of protein was separated by SDS-PAGE, 
transferred onto a nitrocellulose membrane and probed with antibodies against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), E-cadherin, transforming growth 
factor beta 1 receptor 2 (TGF-β1R2), vimentin (GeneTex), cofilin and angiotensin II type 
2 receptor AT2R (Abcam). Secondary antibodies were Horseradish peroxidase-linked 
anti-rabbit or anti-mouse (GeneTex). Proteins were detected using ImmunStar Western C 
(Bio-rad Laboratories). Chemiluminescent signals were detected using FluorChem M 
System (Protein Simple). Protein expression was quantified by densitometry using the 
Image J software and normalized to GAPDH or cofilin.    
 
2.7 Statistical Analysis 
Kaplan-Meier survival analysis was used to analyze survival data. Biochemical and 
histological data were analyzed using one-way ANOVA. All other data were analyzed 
using unpaired Student’s t-test. All statistical analysis was performed using GraphPad 
Prism version 7.0. P-values < 0.05 were considered statistically different.  
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Chapter 3  
3 Results 
3.1 Daily administration of GYY4137 increases H2S levels 
in urine  
To investigate if GYY4137 (200 µmol/kg) administered daily through IP injections 
released and delivered H2S to the kidneys, we used MeRho-Az, a fluorescent H2S probe, 
to measure urinary H2S levels. After three days of UUO, urine obtained directly from the 
obstructed ureter of GYY4137-treated rats had significantly higher levels of H2S (p<0.05) 
compared to UUO rats (Figure 2).  
 
Figure 2. Urinary H2S levels increase upon daily IP injection with GYY4137. Urine 
was obtained directly from obstructed kidney in UUO (n=5, 1mL PBS IP daily) and UUO 
+ GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily) rats on POD 3. 200 
µM of MeRho-Az fluorescent H2S probe was added immediately upon urine collection 
and samples were flash frozen in liquid nitrogen. Urinary concentration of H2S was 
determined based on fluorescence intensity. Values are mean ± SEM. †p<0.05 vs. UUO  
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3.2 Supplemental H2S slightly improves post-obstructive 
survival rates following prolonged UUO 
After relief of obstruction and reimplantation, we observed a slight improvement in 
survival rates in GYY4137-treated groups compared to UUO-R group. While all 
GYY4137-treated animals survived until POD 30, two animals in the UUO-R group did 
not survive past POD 19 (Figure 3).   
 
 
Figure 3. H2S treatment slightly improves survival of animals post-obstruction. 
Survival rates of Sham (n=5), UUO-R (n=10, 1mL PBS IP daily), UUO-R + 14 Day 
GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-14), UUO-R + 
30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-30) 
animals. Blue line indicates day of reimplantation surgery (day 14).  
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3.3 H2S treatment helps to improve renal function during 
UUO and enables earlier recovery of renal function 
post-obstruction  
On POD 3 and 7, serum creatinine levels of UUO-R rats were significantly higher than 
Sham-operated rats (p<0.01). Serum creatinine levels of GYY4137-treated rats were also 
significantly higher than Sham on POD 7 (p<0.05). However, serum creatinine levels of 
GYY4137-treated animals were not higher than Sham on POD 3 and 10. All 
experimental groups exhibited significantly higher serum creatinine levels when 
compared to Sham (p<0.05) following decompression. Interestingly, while UUO-R, 
UUO-R + 14 Day GYY4137 and UUO-R + 30 Day GYY4137 groups all exhibited 
higher serum creatinine levels than Sham on POD 17 (p<0.0001, p<0.01, p<0.05, 
respectively), continuous administration of GYY4137 upon relief of obstruction resulted 
in a marked reduction in serum creatinine levels when compared to UUO-R group on 
POD 17 (Figure 4A).  
 
Serum cystatin C levels of all experimental groups were higher than Sham on POD 18 
(p<0.05), however, treatment with GYY4137 markedly reduced serum cystatin C levels 
when compared to UUO-R animals (Figure 4B). Cystatin C levels in UUO-R, UUO-R + 
14 Day GYY4137 and UUO-R + 30 Day GYY4137 animals were not different from 
Sham on POD 30 (Figure 4B). 
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Figure 4. Daily administration of H2S accelerates the recovery of renal function 
following the relief of UUO. Serum samples were obtained on POD 3, 7 10, 17, 21, 24 
and 30 from Sham (n=5), UUO-R (n=10, 1mL PBS IP daily), UUO-R + 14 Day 
GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-14), UUO-R + 
30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-30) rats 
for analysis of A) creatinine levels and normalized to body weight on day of serum 
collection and B) cystatin C levels. Values are mean ± SEM. Blue dashed line indicates 
day of reimplantation. * p<0.05, **p<0.01, *** p<0.001, **** p<0.0001 vs Sham. 
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3.4 Exogenous H2S helps to regulate sodium excretion 
shortly after relief of obstruction  
The fractional excretion of sodium (FENa) of UUO-R, UUO-R + 14 Day GYY4137 and 
UUO-R + 30 Day GYY4137 groups were drastically higher when compared to Sham on 
POD 17. Though not statistically different, FENa of GYY4137-treated animals was 
considerably lower than UUO-R animals on POD 17 (Figure 5).  The FENa of UUO-R, 
UUO-R + 14 Day GYY4137, and UUO-R + 30 Day GYY4137 were all similar to Sham 
on POD 30 (Figure 5).  
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Figure 5. Daily administration of H2S markedly decreases the fractional excretion of 
sodium at POD 17. Urine and serum samples were obtained on POD 17 and 30 from 
Sham (n=5), UUO-R (n=10, 1mL PBS IP daily), UUO-R + 14 Day GYY4137 (n=11, 200 
µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-14), UUO-R + 30 Day GYY4137 
(n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-30) rats for analysis. Values 
are mean ± SEM. 
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3.5 Administration of H2S moderately modulates proteinuria  
During the obstruction period, 24-hour total urine protein excretion in obstructed animals 
was similar to Sham-operated animals (Figure 6). Following the relief of obstruction, 
urinary protein levels were remarkably higher in all experimental groups when compared 
to Sham group. On POD 17, urine protein was significantly increased in UUO-R animals 
when compared to Sham on (p<0.05), however administration of GYY4137 following 
relief of obstruction led to a moderate decrease in urine protein excretion. On all other 
post-obstructive days, urine protein in UUO-R group was considerably higher when 
compared to Sham, though not statistically significant. Treatment with GYY4137 
resulted in a trend towards a decrease in urine protein when compared to UUO-R group 
(Figure 6).  
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Figure 6. Supplemental H2S moderately reduces proteinuria. Urine samples were 
obtained on POD 3, 7 10, 17, 21, 24 and 30 from Sham (n=5), UUO-R (n=10, 1mL PBS 
IP daily), UUO-R + 14 Day GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, IP 
daily POD 1-14), UUO-R + 30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL 
PBS, IP daily POD 1-30) rats for quantification of urine protein concentration and 24 
hour urine volume. 24 hour urine protein excretion was quantified. Values are mean ± 
SEM. Blue dashed line represents day of reimplantation. *p<0.05 vs. Sham 
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3.6 Supplemental H2S reduces cortical loss following relief 
of urinary obstruction 
To evaluate the effect of GYY4137 on renal architecture following UUO-R, kidney 
sections were stained with H&E and cortical thickness was measured by a blinded renal 
pathologist (Figure 7A). On POD 18, rats in the UUO-R and UUO-R + 14 Day 
GYY4137 group both had significantly decreased renal cortical thickness when compared 
to Sham (p<0.05).  The cortical thickness of UUO-R and UUO-R + 14 Day GYY4137 
were all significantly lower on POD 30 when compared to Sham (p<0.05), however, 30-
day treatment with GYY4137 significantly rescued cortical loss when compared to UUO-
R POD 30 (p<0.05, Figure 7B).  
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A)  
 
 
B)  
 
Figure 7. H2S modulates cortical loss associated with UUO following decompression. 
Kidney samples were obtained from Sham (n=5), UUO-R (n=10, 1mL PBS IP daily), 
UUO-R + 14 Day GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 
1-14), UUO-R + 30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily 
POD 1-30) rats on POD 18 and POD 30. Sections were stained with H&E. A) 
Representative whole-slide scans of kidney sections. B) Cortical thickness was measured 
by a blinded renal pathologist. Values are mean ± SEM. *p<0.05 vs Sham POD30, 
†p<0.05 vs UUO-R POD30.  
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3.7 H2S mitigates renal apoptosis following relief of long-
term UUO 
Tissue sections were stained with TUNEL to quantified the number of apoptotic cells 
(Figure 8A).  When compared to Sham-operated animals, UUO-R animals had a marked 
increase in renal apoptosis on POD 18 and UUO-R + 14 Day GYY4137 animals 
exhibited significantly higher levels of apoptosis (p<0.05) on POD 18.  The UUO-R + 14 
Day GYY4137 group have a considerably lower level of apoptosis when compared to 
UUO-R group on POD 18, though not statistically significant.  While UUO-R and UUO-
R + 14 Day GYY4137 group both exhibited significantly higher levels of apoptosis when 
compared to Sham (p<0.01 and p<0.05, respectively), UUO-R + 30 Day GYY4137 group 
had similar levels of apoptosis when compared to Sham on POD 30. Renal apoptosis 
associated with UUO-R was significantly ameliorated on POD 30 upon 30 days of 
GYY4137 treatment (p<0.01), and interestingly, 30-day administration of GYY4137 led 
to a significant decrease in apoptosis when compared to 14-day GYY4137 treatment 
(p<0.05, Figure 8B).    
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B) 
 
Figure 8. Daily treatment with H2S mitigates apoptosis following relief of urinary 
obstruction. Terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling 
(TUNEL) staining of kidneys following Sham (n=5), UUO-R (n=10, 1mL PBS IP daily), 
UUO-R + 14 Day GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 
1-14), UUO-R + 30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily 
POD 1-30) on POD18 and POD30.  A) Representative images of sections stained with 
TUNEL at 10x magnification. B) Median cell count of 5 randomly acquired images at 
10x magnification, quantified using ImageJ. Bar represents mean.  * p<0.05, **p<0.01, 
vs Sham POD30, ††p<0.05 vs UUO-R POD30, #p<0.05 vs UUO-R + 14 Day GYY4137 
Sh
am
Da
y 1
8
Da
y 3
0
0
20
40
60
80
100
500
1000
1500
Post-operative day
A
po
pt
ot
ic
 c
el
ls
Sham
UUO-R
UUO-R + 14 Day GYY4137
UUO-R + 30 Day GYY4137
**
*
*
††#
36 
 
3.8 H2S mitigates neutrophil infiltration  
To determine the effects of GYY4137 on neutrophil infiltration, kidney sections were 
immunohistochemically stained with antibody against MPO (Figure 9A). On POD 18, 
UUO-R group exhibited significantly higher levels of neutrophil infiltration when 
compared to Sham (p<0.05), while UUO-R + 14 Day GYY4137 group did not. While it 
was not statistically significant, the number of neutrophils in the UUO-R + 14 Day 
GYY4137 group was considerably lower when compared to UUO-R group on POD 18 
(Figure 9B).  On POD 30, UUO-R groups exhibited significantly higher levels of 
neutrophil infiltration when compared to Sham (p<0.05). UUO-R + 14 Day GYY4137 
and UUO-R + 30 Day GYY4137 groups, however, were similar to Sham on POD 30. 
Moreover, UUO-R + 30 Day GYY4137 animals exhibited significantly lower levels of 
neutrophil infiltration when compared to UUO-R (p<0.05, Figure 9B).  
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A) 
 
 
B) 
 
Figure 9. Supplemental H2S reduces neutrophil infiltration following long-term 
UUO and relief of obstruction.  Immunohistochemistry staining of kidneys on POD 18 
and 30 from Sham (n=5), UUO-R (n=10, 1mL PBS IP daily), UUO-R + 14 Day 
GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-14), UUO-R + 
30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily POD 1-30) rats 
using antibody against myeloperoxidase (MPO). A) Representative images of sections 
taken at 10x magnification. B) MPO-positive cells were quantified using ImageJ. Data 
represents median cell count of 5 randomly acquired images. Bar represents mean.           
* p<0.05, ** p<0.01 vs Sham POD30, †p<0.05 vs UUO-R POD30 
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3.9  Supplemental H2S mediates macrophage infiltration 
Kidney sections were immunohistochemically stained with antibodies against CD68 to 
determine the effects of GYY4137 on macrophage infiltration (Figure 10A).  Compared 
to Sham, the level of macrophage infiltration in UUO-R and UUO-R + 14 Day GYY4137 
animals were significantly higher on POD 18 and POD 30 (p<0.0001 and p<0.05 on POD 
18, p<0.001 and p<0.01 on POD 30, respectively).  While it was not statistically 
significant, there was a considerable decrease in macrophage infiltration in UUO-R + 14 
Day GYY4137 when compared to UUO-R on POD 18 (Figure 10B). There was no 
difference in macrophage infiltration between Sham and UUO-R + 30 Day GYY4137 
animals on POD 30.  Interestingly, on POD 30, not only was the macrophage infiltration 
significantly lower in UUO-R + 30 Day GYY4137 when compared to UUO-R 
(p<0.0001), it was also significantly lower than UUO-R + 14 Day GYY4137 (p<0.001, 
Figure 10B). To further elucidate the subtypes of infiltrating macrophages, kidney 
sections were immunofluorescently stained with antibodies against CD68 and CD206 
(Figure 10C). M2 macrophages were deemed to be both CD68-positive and CD206-
positive, and expressed as a percentage of total CD68-positive cells (Figure 10C). 
Interestingly, there was a significant increase in M2 macrophage infiltration in UUO-R + 
14 Day GYY4137 group, but not UUO-R group, on POD 18 when compared to Sham 
(p<0.05). While not statistically significant, the infiltration of M2 macrophages was 
slightly higher in the UUO-R + 14 Day GYY4137 group when compared to UUO-R 
group on POD 18 (Figure 10D). The population of M2 macrophages in UUO-R, UUO-R 
+ 14 Day GYY4137 and UUO-R + 30 Day GYY4137 was no different from Sham on 
POD 30 (Figure 10D).   
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D) 
 
Figure 10. GYY4137 mediates macrophage infiltration in urinary obstruction. 
Kidney samples were obtained on POD 18 and 30 from Sham (n=5), UUO-R (n=10, 1mL 
PBS IP daily), UUO-R + 14 Day GYY4137 (n=11, 200 µmol/kg GYY4137 in 1 mL PBS, 
IP daily POD 1-14), UUO-R + 30 Day GYY4137 (n=5, 200 µmol/kg GYY4137 in 1 mL 
PBS, IP daily POD 1-30) rats. A) Representative images of sections stained with 
antibody against CD68 via IHC at 10x magnification. B) Positively stained cells were 
quantified using ImageJ. Data represents median cell count of 5 randomly acquired 
images at 10x magnification. Bar represents mean. C) Immunofluorescent staining of 
sections using antibodies against CD68 (blue) and CD206 (green). 5 images were 
acquired at random at 40x magnification. D) Using ImageJ to quantify positively-stained 
cells, CD68+/CD206+ cells (cyan) was normalized to CD68+ (blue). Data represents 
median percentage of M2 macrophage relative to total macrophage infiltrate. Bar 
represents mean.  * p<0.05, **p<0.01, ***p<0.001 vs Sham POD30, ††††p<0.0001 vs 
UUO-R POD30, ###p<0.001 vs UUO-R + 14 Day GYY4137 POD 30. 
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3.10 Exogenous H2S ameliorates renal fibrosis following 
relief of prolonged UUO 
Kidney sections were stained with Masson’s trichrome to determine the level of renal 
fibrosis following decompression of long-term UUO (Figure 11A). On POD 18, UUO-R 
animals, but not UUO-R + 14 Day GYY4137 animals, exhibited significantly higher 
levels of fibrosis when compared to Sham (p<0.05). While not statistically significant, 
UUO-R + 14 Day GYY4137 animals had slightly lower levels of renal fibrosis when 
compared to UUO-R animals on POD 18 (p=0.0732, Figure 11B). When compared to 
Sham, UUO-R, UUO-R + 14 Day GYY4137 and UUO-R + 30 Day GYY4137 animals 
all exhibited significantly higher levels of renal fibrosis on POD 30 (p<0.001, p<0.05, 
and p<0.05, respectively). Interestingly, both 14-day and 30-day treatment with 
GYY4137 significantly reduced renal fibrosis when compared to UUO-R animals on 
POD 30 (p<0.05, Figure 11B).  
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A) 
 
 
B)  
 
Figure 11. H2S treatment mitigates renal fibrosis following prolonged UUO and 
decompression.  Kidneys were obtained on POD 18 and 30 from Sham (n=5), UUO-R 
(n=10, 1mL PBS IP daily), UUO-R + 14 Day GYY4137 (n=11, 200 µmol/kg GYY4137 
in 1 mL PBS, IP daily POD 1-14), UUO-R + 30 Day GYY4137 (n=5, 200 µmol/kg 
GYY4137 in 1 mL PBS, IP daily POD 1-30) rats. A) Sections were stained with 
Masson’s trichrome. Representative images of sections taken at 10x magnification. B) 
Fibrotic areas were quantified using ImageJ. Data represents median percentage of 
fibrosis of 5 randomly acquired images. Bar represents mean. * p<0.05, ***p<0.001 vs 
Sham POD30, †p<0.05 vs UUO-R POD30. 
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3.11 H2S attenuates the TGF-β1-mediated EMT pathway in 
vitro 
To further evaluate the role of GYY4137 on fibrosis and elucidate potential mechanisms 
of action, rat kidney epithelial (NRK52E) cells were treated with 10 ng/mL TGF-β1 to 
induce EMT in the presence or absence of GYY137. Western blot analysis was 
completed to determine the expression of E-cadherin, vimentin, TGF-β1R2, Smad3, 
Smad7, and angiotensin II type 2 receptor (Figure 12).   
  
Both 10 and 50 µM of GYY4137 alone had no effect on E-cadherin expression when 
compared to untreated cells. Interestingly, E-cadherin expression was significantly 
reduced upon treatment with 10 ng/mL TGF-β1 (p<0.01); however, the effect of TGF-β1 
was slightly attenuated in the presence of 10 µM GYY4137 and significantly abrogated 
in the presence of 50 µM GYY4137 (p<0.05, Figure 12A).  The expression of vimentin 
in NRK52E cells remained unchanged relative to untreated cells in the presence of 10 
ng/mL TGF-β1, 10 µM GYY4137 and 50 µM GYY4137. However, when compared to 
TGF-β1-treated cells, the expression of vimentin was slightly decreased in 10ng/mL 
TGF-β1 + 10 µM GYY4137 cells, and significantly reduced in 10ng/mL TGF-β1 + 50 
µM GYY4137 cells (p<0.05, Figure 12A).  
 
Relative to untreated cells, Western blot analysis showed that the expression of Smad3 in 
10 ng/mL TGF-β1, 10 µM GYY4137, 50 µM GYY4137, and 10 ng/mL TGF-β1 + 10 
µM GYY4137-treated cells remained unchanged (Figure 12B). However, when 
compared to 10 ng/mL TGF-β1-treated cells, expression of Smad3 was significantly 
reduced (p<0.05) upon additional treatment with 50 µM GYY4137 (Figure 12B). 
Similarly, the expression of Smad7 in NRK52E cells remained unchanged in the presence 
of 10 ng/mL TGF-β1, 10 µM GYY4137, and 50 µM GYY4137 relative to untreated 
cells. However, when compared to TGF-β1-treated cells, expression of Smad7 was 
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slightly increased in 10 ng/mL TGF-β1 + 10 µM GYY4137-treated cells and significantly 
increased in 10 ng/mL TGF-β1 + 50 µM GYY4137-treated cells (p<0.05, Figure 12B).  
 
In the presence of 10 or 50 µM GYY4137 only, the expression of TGF-β1R2 in NRK52E 
cells remained unchanged relative to untreated cells. However, stimulating NRK52E cells 
with 10ng/mL TGF-β1 significantly increased the expression of TGF-β1R2 (p<0.05) 
when compared to untreated cells. While this effect was not attenuated when 10 µM 
GYY4137 was added, the effect of TGF-β1 on TGF-β1R2 expression was significantly 
reduced upon treatment with 50 µM GYY4137 (p<0.05, Figure 12C).  While not 
statistically different, the expression of AT2R was slightly decreased in the presence of 
10 ng/mL TGF-β1 when compared to untreated cells. Treatment with 10 µM GYY4137 
and 50 µM GYY4137 had no effect on AT2R expression when compared to untreated 
cells.  When compared to 10 ng/mL TGF-β1-treated cells, the expression of AT2R in 10 
ng/mL TGF-β1 + 10 µM GYY4137 remained unchanged, however, a slight increase in 
AT2R expression was observed in 10 ng/mL TGF-β1 + 50 µM GYY4137-treated cells, 
though it was not statistically significant (Figure 12C).  
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Figure 12.	H2S mitigates the TGF-β1-induced epithelial-mesenchymal transition in 
NRK52E cells. NRK52E cells were subjected to treatment with 10 ng/mL TGF-β1, 10 
µM GYY4137, 50 µM GYY4137, 10 ng/mL TGF-β1 + 10 µM GYY4137, 10 ng/mL 
TGF-β1 + 50 µM GYY4137, or left untreated in serum-free media (FBS-) for 48 hours. 
Total protein was isolated and assess for expression of A) E-cadherin and vimentin, B) 
Smad3 and Smad7, and C) TGF-β1R2 and AT2R, as well as housekeeping genes 
GAPDH and cofilin by means of western blot analysis.  Expression levels were 
quantified by densitometry using ImageJ software and normalized to housekeeping 
genes. Data represents protein expression relative to FBS-. Data are mean ± SEM, n=3. 
*p<0.05 vs FBS-, †p<0.05 vs 10 ng/mL TGF-β1 
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Chapter 4  
4 Discussion 
4.1 Summary of study 
If prolonged, urinary obstruction can lead to disruption of hemodynamics and renal 
function, such as reduced renal blood flow and defective sodium/potassium ATPase 
pumps (Klahr 2000).   In addition, the accumulation of ROS can cause tubular injury and 
cell death and potentiate tissue inflammation (Ucero et al. 2014). These infiltrating 
leukocytes express a large variety of cytokines, including TGF-β1, a critical player in the 
induction of tissue fibrosis. Through the well-characterized Smad-dependent EMT 
pathway, TGF-β1 stimulates fibrosis and increases collagen deposition in the 
tubulointerstitial space (Ucero et al. 2014). It is important to note that, while obstructions 
can be surgically removed, renal function may not fully recovery as it is dependent on the 
duration and severity of the obstruction (Vaughan JR. & Gillenwater 1971).  Although 
current pharmacological treatments may mediate pain associated with urinary 
obstruction, they do not attenuate the accumulation of renal injury. As a result, permanent 
renal dysfunction may occur following decompression. Thus, pre-emptively limiting 
renal injury during the course of obstruction may potentially improve renal function 
following relief of urinary obstruction (Chevalier et al. 1999). 
 
Evidence suggests that H2S, an endogenously produced gaseous molecule, can cause 
vasodilation, scavenge ROS, and ameliorate apoptosis, inflammation, EMT and fibrosis 
in various models of tissue injury (Wang 2002; Lobb et al. 2014; Jung et al. 2013; Song 
et al. 2014).   We have recently shown that GYY4137, a slow-releasing H2S donor, can 
mitigate renal injury and fibrosis in long-term UUO (Lin et al. 2016). Taken together, 
these studies suggest that H2S may be a potential therapy against renal injury associated 
with UUO. However, the UUO model is limited in its ability to provide accurate 
functional data. Therefore, in this study, we employed a rat model of UUO-R (a 
reversible UUO model) to evaluate the effects of H2S donor GYY4137 on renal function 
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and renal injury following relief of prolonged urinary obstruction. Furthermore, using an 
in vitro model of EMT, we elucidated potential mechanisms of action. We found that 
daily administration of GYY4137 improved renal function and mitigated renal injury.  
Our data suggests that GYY4137 may attenuate fibrosis by modulating the TGF-β1-
mediated, Smad-dependent EMT pathway.  
 
4.2 H2S from GYY4137 localizes to the kidney 
NaHS and Na2S are two of the most commonly-used exogenous H2S molecules in the 
literature. These sulfide salts readily deliver H2S in solution, and due to their widespread 
availability, are easily accessible. However, sulfide salts release supra-physiological 
amounts of H2S rapidly, and thus fail to mimic the physiological production of H2S. In 
addition, the uncontrolled release of H2S can lead to off-target effects (Rose et al. 2015).  
To overcome this shortcoming, there has been a recent burst in the development of 
organic molecules that slowly release H2S to better mimic endogenous H2S production. 
 
GYY4137 is a slow-releasing H2S donor that has been shown to exhibit vasodilatory, 
antihypertensive, and anti-inflammatory effects (Li et al. 2008; Li et al. 2013).  Previous 
studies have shown that, unlike NaHS, intravenous and intraperitoneal injections of 
GYY4137 resulted in a sustained increase of plasma H2S, suggesting that GYY4137 
releases H2S slowly over time and causes a systemic elevation in H2S (Li et al. 2008). 
However, we sought to determine whether intraperitoneal injection of GYY4137 causes 
H2S to reach the kidneys. As such, we obstructed the ureter for 3 days, with or without 
daily IP injections of GYY4137, then collected the kidney directly from the obstructed 
ureter. Using MeRho-Az, a fluorescent H2S probe (Hammers et al. 2015), we found 
increased levels of urinary H2S in animals treated with GYY4137 (Figure 2). Taken 
together, these results suggest that the H2S released from GYY4137 localizes to the 
kidneys. 
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4.3 H2S accelerates the recovery of renal function 
Prolonged complete UUO inflicts severe damage to the obstructed kidney, leading to 
irreversible renal injury and dysfunction (Ucero et al. 2014). After 14 days of complete 
UUO, two animals in the UUO-R group died of renal failure following decompression, 
however, supplemental H2S led to 100% survival rate post-decompression (Figure 3). 
This suggests that H2S treatment could potentially be used as a treatment in UUO to 
minimize renal injury and improve functional recovery.  
 
Serum creatinine and serum cystatin C are commonly-used indicators of renal function.  
During the obstructive phase, serum creatinine was significantly higher in UUO-R 
animals on POD 3 and 7, but with time, recovered back to Sham levels on POD 10. Liu et 
al. have observed a similar trend in a porcine model of UUO. When compared to pre-
obstructive values, serum creatinine collected from bilateral renal veins and precaval 
veins were all significantly higher in UUO pigs (Liu et al. 2016).  This suggests that 
UUO not only affects renal function of the obstructed kidney, but it has a moderate 
impact the contralateral kidney as well, thus resulting in a systemic elevation of serum 
creatinine.  
 
Following relief of obstruction, we also removed the contralateral kidney such that the rat 
is dependent solely on the previously obstructed kidney. As expected, serum creatinine of 
experimental groups was elevated on POD 17, and despite a moderate decline over time, 
remained elevated on all post-operative days following decompression (Figure 4A). Our 
serum cystatin C data mirrored this trend; we observed an increase in serum cystatin C in 
all experimental groups on POD 18 when compared to Sham. By POD 30, a drastic 
decrease in serum cystatin C is observed, however it remains considerably higher than 
Sham  (Figure 4B). This implies that prolonged urinary obstruction inflicts severe renal 
injury, and that recovery of renal function may not be complete despite surgical 
decompression (Vaughan JR. & Gillenwater 1971; Chaabane et al. 2013). However, we 
53 
 
observed a considerable decrease in serum creatinine on POD 17 in our 30-day 
GYY4137 treatment group, when compared to UUO-R (Figure 4A). This trend was also 
observed in our cystatin C data. While all experimental groups exhibited significantly 
higher serum cystatin C when compared to Sham on POD 18, GYY4137 treatment 
resulted in a moderate decrease in serum cystatin C. While it was not statistically 
significant, this reduction in serum creatinine and cystatin C could have important 
clinical and biological implications, and may suggest that GYY4137 treatment can lead 
to an earlier recovery of renal function following the relief of urinary obstruction. H2S 
could play a role in accelerating the recovery of renal function, as previously also 
demonstrated in IRI and transplant studies (Lobb et al. 2012).  
 
Post-obstructive diuresis is a characterized by heightened excretion of water and 
electrolytes following the relief of urinary obstruction. In rats, this can be observed 
following bilateral ureteral obstruction or UUO with contralateral nephrectomy (Harris & 
Yarger 1975). Post-obstructive diuresis can be caused by improper tubular reabsorption, 
and as a result, a robust increase in FENa is typically observed following decompression 
(Harris & Yarger 1975). In present study, we observed a drastic increase in FENa in all 
experimental groups 3 days following relief of obstruction and contralateral nephrectomy 
when compared to sham-operated animals (Figure 5). However, this was markedly 
ameliorated upon daily treatment of GYY4137, and interestingly, continuous 
administration of GYY4137 following relief of obstruction resulted in a more evident 
reduction of FENa (Figure 5).  It is well-established that Na+/K+ ATPases are critical in 
the maintenance of tubular sodium reabsorption and disruption of these channels can lead 
to increased FENa(Li et al. 2003). Previous studies have shown that the downregulation 
of tubular Na+/K+ ATPases typically seen in UUO is likely a result of oxidative stress, 
which was mitigated upon administration of anti-oxidant apocynin (Liu et al. 2015).  It is 
likely that H2S donor GYY4137 was protective in the same manner; due to its anti-
oxidant properties, it was able to mitigate the downregulation of Na+/K+ ATPases 
channels during UUO (Cao & Bian 2016).  While all groups exhibit a slight recovery of 
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post-obstructive FENa by POD 30, it is important to note that GYY4137 accelerated the 
reduction of FENa after decompression.   
 
Taken together, our data suggest that recovery of renal function following prolonged 
UUO was not complete despite surgical decompression. However, treatment with H2S 
donor GYY4137 during both the obstructive and recovery phase was beneficial as it 
accelerated the recovery of renal function as exemplified by the reduction of serum 
creatinine, serum cystatin C and FENa.  
 
4.4 Daily administration of H2S mitigates renal injury 
To investigate the effect H2S on renal injury associated with UUO and decompression, 
we evaluated 24-hour total urine protein excretion as proteinuria is a well-established 
marker of renal injury. In the obstructive phase, 24-hour total urinary protein excretion 
remained the same across all experimental groups (Figure 6), likely due to the 
compensatory action of the contralateral kidney. However, following relief of obstruction 
and contralateral nephrectomy, we observed a significant increase in proteinuria in UUO-
R group when compared to Sham. This was slightly mitigated upon treatment with 
GYY4137 during the obstructive phase (Figure 6).  Proteinuria can be a sign of 
hypertensive injury (Helal et al. 2012; Lin et al. 2016). As previous studies have 
demonstrated that ACE inhibitors and angiotensin II type 1 receptor (AT1R) antagonists 
can reduce tissue damage and proteinuria (Suzuki et al. 2007), this suggests that the 
vasodilatory effects of H2S could play a role in mediating proteinuria and highlights its  
ability to regulate renal pressure (Lobb et al. 2014; Lin et al. 2016). We previously 
demonstrated a downregulation of AT1R expression following H2S treatment in UUO 
(Lin et al. 2016), which suggests that H2S does play an inhibitory role in the RAS.  It is 
interesting to note that Ang II, a key player in regulating blood pressure, binds to both 
AT1R and angiotensin II type 2 receptors (AT2R). However, activation of AT2R 
counteracts the well-established effects of AT1R. In fact, AT2R has been shown to 
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exhibit vasodilatory, anti-inflammatory, anti-fibrotic, and anti-oxidative effects.  In the 
renal system, AT2R has been shown to mediate renal blood flow and hypertensive renal 
disease (Chow & Allen 2016). Suzuki et al. further explored the effect of AT1R and 
AT2R activation in renal injury by examining their role on proteinuria. They discovered 
that the administration of AT1R antagonist ameliorated proteinuria, while treatment with 
AT2R agonist enhanced the expression of glomerular barrier proteins and led to decrease 
proteinuria (Suzuki et al. 2007).  Furthermore, studies have shown the importance of NO 
in mediating AT2R expression and its corresponding vasodilatory effects (Chow & Allen 
2016). As H2S share a multitude of properties, particularly vasodilation, with its 
gasotransmitter family member NO, it is possible that administration of H2S may have 
ameliorated proteinuria associated with urinary obstruction in a similar fashion. Further 
studies are required to determine the exact relationship and mechanism of action between 
H2S and AT2R.   
 
Proteinuria can also occur due to hyperfiltration, which is often a result of nephron loss 
and reduction of renal cell mass (Helal et al. 2012). As H2S  has been shown to increase 
tubular regeneration, it is possible that daily supplementation with H2S mitigated 
proteinuria by preserving renal architecture (Han et al. 2015; Lobb et al. 2015), thus 
diminishing hyperfiltration. This mirrors our histopathological data (Figure 6), where we 
demonstrate the ability of H2S to rescue cortical loss associated with UUO.  
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4.5 H2S mitigates the histopathological markers of renal 
injury following the relief of urinary obstruction 
Significant cortical loss was observed in UUO-R and UUO-R + 14 Day GYY4137 
groups on POD 18 and POD 30 when compared to Sham, however, we did not detect a 
difference in cortical thickness between UUO-R and UUO-R + 14 Day GYY4137 animal 
(Figure 7). The loss of renal cortex could be attributed to tissue atrophy and loss 
glomerular volume (Chaabane et al. 2013), which corresponds with the loss of renal 
function observed.  Although we previously demonstrated that GYY4137 treatment 
helped to preserve renal architecture in UUO, this discrepancy may be due to the 
difference in injury model. Our previous study employed a 30-day obstruction model, 
which is much more severe than our current 14-day obstruction model; thus, the observed 
injury of UUO and protective effects of GYY4137 were more distinct (Lin et al. 2016). It 
is possible that we were not able to detect the subtler effects of GYY4137 in our present 
study. Interestingly, GYY4137 treatment both during obstruction and following 
decompression lead to a significant reduction in cortical loss when compared to UUO-R 
group on POD 30 (Figure 7). Previous studies have shown that H2S treatment lead to 
increased tubular proliferation and regeneration in ischemia-reperfusion injury by 
regulating cellular proliferation genes and maintaining blood flow (Han et al. 2015; Lobb 
et al. 2015).  Taken together, this suggests that H2S can protect the kidney from cortical 
loss during prolonged UUO and treatment with H2S post-obstruction aids in recovery by 
accelerating tubular proliferation. These observed effects are likely attributed to the well-
established ability of H2S to regulate blood flow (Xia et al. 2006).   
 
Using TUNEL staining, we evaluated the effects of H2S on renal apoptosis 4 and 16 days 
post-decompression of 14-day obstruction.  Unlike our previous 30-day UUO model, we 
were able to detect changes in renal apoptosis. Previous studies have shown that levels of 
apoptosis are elevated after 4 to 15 days of obstruction.  However, a decline in apoptosis 
is observed after more than 15 days of obstruction as the kidney starts to exhibit more 
chronic injury phenotype (Truong et al. 1996; Lin et al. 2016). This suggests that 
apoptosis is an acute marker of renal injury and our previous 30-day obstruction model 
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resulted in a chronic injury phenotype.  In present study, both UUO-R and UUO-R + 14 
Day GYY4137 groups exhibited remarkable increase in renal apoptosis on POD 18 when 
compared to Sham.  Although it was not statistically significant, treatment with 
GYY4137 throughout the course of obstruction slightly reduced renal apoptosis when 
compared to UUO-R animals. Apoptosis continues to be elevated in UUO-R and UUO-R 
+ 14 Day GYY4137 groups on POD 30, however, continuous treatment with GYY4137 
following the relief of obstruction mitigated renal apoptosis (Figure 8). This is likely due 
to the well-established anti-apoptotic effects of H2S and its ability to scavenge the ROS 
that accumulated from UUO (Szabó 2007; Koning et al. 2015).  
 
To assess the effects of GYY4137 on inflammation, we quantified neutrophil and 
macrophage infiltration via IHC staining.  As expected, a significant increase in 
neutrophil infiltration was observed in UUO-R and UUO-R + 14 Day GYY4137 animals 
on POD 18 and 30. Similar to our previous study, administration of H2S during the 
course of obstruction slightly reduced neutrophil infiltration on POD 18 when compared 
to UUO-R group (Lin et al. 2016).  Interestingly, we observed a significant reduction in 
neutrophil infiltration in animals that continued to receive H2S treatment following 
decompression when compared to untreated animals and animals that received H2S 
treatment during the obstruction phase alone (Figure 9). Similarly, there was a significant 
increase in macrophage infiltration on POD 18 in both UUO-R and UUO-R + 14 Day 
GYY4137 groups on POD 18, however, the administration of GYY4137 led to a slight 
reduction in inflammation.  We also observed a significant reduction in macrophage 
infiltration in animals that were given GYY4137 post-obstruction (Figure 9B). This is 
likely attributed to the well-established abilities of H2S to decrease leukocyte adhesion to 
vascular endothelial cells, inhibit the secretion of pro-inflammatory cytokines and 
stimulate the production of anti-inflammatory cytokines (Li et al. 2013; Szabó 2007).  
 
The microenvironment of the kidney may alter macrophage activation and polarize 
macrophages towards M1 or M2 phenotypes. Classically activated (M1) macrophages 
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produce cytokines that induce inflammation and apoptosis, while alternatively activated 
(M2) macrophages secrete anti-inflammatory cytokines and contribute to tissue repair 
and regeneration (Kluth et al. 2004).  We sought to distinguish the population of 
macrophages in renal tissue and evaluate the effects of H2S on macrophage polarization. 
Through immunofluorescent staining with macrophage marker CD68 and M2 marker 
CD206, we observed a significant increase in relative M2 population in UUO-R + 14 Day 
GYY4137 groups on POD 18 when compared to Sham, and a moderate increase when 
compared to UUO-R group (Figure 10D). This was expected, as studies have also 
observed an increase in relative M2 population following H2S supplementation in 
myocardial infraction and a corresponding recovery of cardiac function (Miao et al. 
2016). Taken together, our data suggest that H2S helps to resolve inflammation by 
reducing total neutrophil and macrophage infiltration (Figures 9B and 10B), however, the 
increase in proportion of M2 macrophages implies that H2S either drives macrophages 
towards the M2 phenotype or depletes the relative proportion of pro-inflammatory M1 
macrophages. It is possible that the reparative and anti-inflammatory properties of M2 
macrophages may have also contributed to an earlier recovery of renal function following 
decompression (Miao et al. 2016).  
 
Tubulointerstitial fibrosis is a hallmark of CKD and manifests as deposition of ECM into 
the interstitial space. After prolonged UUO, tubulointerstitial fibrosis is commonly 
observed and is a sign of severe renal injury (Eddy et al. 2012). To determine the effects 
of H2S following relief of UUO, we stained tissue sections with Masson’s trichrome and 
observed a significant increase in renal fibrosis in UUO-R group on POD 18, and this 
remains elevated up until POD 30.  GYY4137 treatment mitigated fibrosis on PODs 18 
and 30 when compared to UUO-R group (Figure 11). Previous studies, including ours, 
observed a similar anti-fibrotic effect following administration of H2S, which suggests 
that H2S plays a protective role in mediating tissue fibrosis (Song et al. 2014; Lin et al. 
2016; Jiang et al. 2013). Interestingly, our study demonstrated that H2S treatment 
mitigated renal fibrosis despite increasing the proportion of M2 macrophages. M2 
macrophages, though anti-inflammatory and reparative, can secrete TGF-β1, which is a 
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known profibrotic cytokine (Meng et al. 2015). The role of M2 macrophages in fibrosis is 
heavily debated in the literature. While some studies have observed M2 macrophages in 
fibrotic regions and a corresponding reduction of fibrosis following depletion of M2 
macrophages (Pan et al. 2015; Shen et al. 2014; Anders & Ryu 2011), others have 
observed a decrease in fibrosis despite a relative increase in M2 infiltration (Kushiyama 
et al. 2011). This suggests that the role of M2 macrophages in fibrotic injury requires 
further investigation. However, it is important to note that TGF-β1 is not exclusively 
profibrotic; it can also play an effective role in abating inflammation (Anders & Ryu 
2011). Additionally, inflammation and epithelial healing are two of the first-line 
responses to injury, and tissue fibrosis only occurs if inflammation is unresolved and 
persistent (Meng et al. 2015; Anders & Ryu 2011).  In this study, we observed a decline 
in total macrophage and neutrophil infiltration following H2S treatment (Figure 9B and 
10B), but an increase in the relative proportion of M2 macrophages (Figure 10D). This 
suggests that overall inflammation was resolved upon H2S supplementation and therefore 
we did not observe an increase in renal fibrosis. Additionally, previous studies have 
shown that H2S treatment mitigates renal fibrosis associated with UUO by mitigating the 
TGF-β1-mediated EMT pathway (Song et al. 2014; Lin et al. 2016; Jiang et al. 2013). 
Therefore, it is possible that the overall anti-fibrotic properties of H2S is two-fold: it 
abrogates fibrosis directly by hindering the progression of EMT and indirectly by 
ameliorating tissue inflammation. To explore the direct anti-fibrotic effect of H2S further, 
we employed an in vitro model of EMT in rat kidney epithelial cells to elucidate the 
potential mechanisms of action.  
 
It is particularly interesting that, despite a significant reduction in histopathological 
markers of renal injury following GYY4137 treatment, we were not able to detect a 
statistical difference in serum creatinine, cystatin C, FENa and urine protein between our 
UUO-R and our GYY4137-treated animals on POD 30.  Our data implies that GYY4137 
treatment may help accelerate the recovery of renal function. Though we were not able to 
detect a functional difference on POD 30, the reduction in histopathological markers of 
renal injury may have important implications on chronic renal function.  In a 
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phenomenon known as “AKI to CKD”, studies have demonstrated that following AKI, 
patients may experience a moderate recovery of renal function, followed by a progressive 
loss of renal function over time (Cerdá et al. 2008). It appears that on POD 21 to POD 30, 
moderate recovery of renal function can be observed in all experimental groups. 
However, GYY4137 treatment resulted in a reduction in the histopathological markers of 
renal injury on POD 30; this could potentially be beneficial for long-term renal function. 
It is possible that GYY4137 can hinder the progression of AKI to CKD by mitigating 
inflammation and fibrosis in the kidney. However, future studies using chronic UUO-R 
models should be conducted to further explore the long-term progression of renal 
function following relief of urinary obstruction.  
 
4.6 Elucidating the potential mechanisms of action  
The increase in TGF-β1 leads to the induction of EMT in renal epithelial cells and 
ultimately results in tubulointerstitial fibrosis characteristic of CKD (Xu et al. 2009).  
Upon stimulation with TGF-β1, renal epithelial cells lose their epithelial properties, often 
characterized by the loss of epithelial marker E-cadherin, and become mesenchymal-like, 
as exemplified by the upregulation of vimentin. These cells can then migrate into the 
interstitial space and secrete ECM components.   This pathway is heavily regulated by 
Smad proteins (it is stimulated by Smad3 and inhibited Smad7 (Ucero et al. 2014; 
Chevalier 2006)), and potentially indirectly abrogated by AT2R (Guo et al. 2016).  We, 
along with others, have previously demonstrated that H2S treatment mitigates renal 
tubulointerstitial fibrosis associated with urinary obstruction (Lin et al. 2016; Jiang et al. 
2013; Song et al. 2014).  To elucidate the mechanism by which GYY4137 ameliorates 
fibrosis, we employed an in vitro model of EMT using rat kidney epithelial cells. 
 
Upon TGF-β1 treatment, a downregulation of E-cadherin and a slight increase in 
expression of vimentin was observed. However, this was slightly abated upon treatment 
with 10 µM of GYY4137 and significantly reduced with 50 µM of GYY4137 (Figure 
61 
 
12A). This suggests that GYY4137 mitigates the TGF-β1-mediated EMT pathway, as 
previously shown (Jiang et al. 2013; Song et al. 2014), and it does so in a dose-dependent 
manner. Furthermore, NRK52E cells treated with 10 µM and 50 µM of GYY4137 alone 
did not express changes in expression of E-cadherin and vimentin (Figure 12A), which 
suggests that GYY4137 does not modulate the expression of EMT markers without TGF-
β1 stimulation.  
 
To further explore the Smad-dependent pathway of EMT, we investigated the expression 
of Smad3 and Smad7 in the presence of TGF-β1 and GYY4137.  Unlike Smad3, Smad7 
antagonizes the TGF-β family signaling pathway as it can cause both Smad3 and TGF-β1 
receptor 1 degradation (Yan et al. 2009). Smad7 is also heavily regulated: it is 
transcriptionally induced in the presence of TGF-β1, however, it itself is degraded in the 
process of degrading the TGF-β receptor 1 (Yan et al. 2009).  The constant turnover of 
Smad7 could have resulted in the seemingly lack of net change in Smad7 expression 
following TGF-β1 treatment (Figure 12B). Furthermore, we did not observe a change in 
total Smad3 expression following TGF-β1 treatment, which was expected as Smad3 is 
activated upon phosphorylation by TGF-β1 receptor (Wolf 2006) and the antibody used 
here only detects total Smad3 expression (Figure 12B). Previous studies have 
demonstrated a decrease in Smad3 phosphorylation following H2S treatment (Song et al. 
2014; Jung et al. 2013), however we were not able acquire a stable phosphorylated-
Smad3 antibody. Interestingly, we observed an upregulation of Smad7 expression and a 
correlating downregulation of total Smad3 expression following treatment with TGF-β1 
+ 50 µM GYY4137 (Figure 12B). This suggests that H2S may impede EMT progression 
by simulating Smad7 production, thereby reducing the number of Smad3s available for 
signal transduction. Our data may have elucidated a potentially novel mechanism by 
which H2S abrogates the progression of EMT, however further studies are required to 
elucidate the exact mechanism of action.  
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The AT2R can exhibit vasodilatory, anti-inflammatory, ant-fibrotic and renoprotective 
effects, and has been shown to counteract the classical vasoconstrictive effects of Ang II 
(Chow & Allen 2016). In addition, it can potentially mitigate fibrosis by decreasing the 
expression of TGF-β1R2 (Chow & Allen 2016; Guo et al. 2016). Interestingly, Guo et al. 
demonstrated that stimulation of AT2R inhibited the progression of TGF-β1-mediated 
EMT, which was heightened upon administration of NO donor SNAP and reversed upon 
treatment with NO synthase inhibitor L-NAME (Guo et al. 2016).  As such, we sought to 
investigate the effects of H2S on AT2R expression. Although not statistically significant, 
treatment with TGF-β1 resulted in a subtle decrease in AT2R expression, which suggests 
that there is an antagonistic relationship between TGF-β1 and AT2R (Guo et al. 2016). 
Interestingly, this corresponded with a significant increase in TGF-β1R2 expression 
(Figure 12C), which was expected as this relationship was previously demonstrated by 
Guo et al (Guo et al. 2016). This effect was moderately reversed with the treatment with 
GYY4137 in a dose-dependent manner, returning the expression of AT2R back to 
baseline levels and significantly reducing the expression of TGF-β1R2 (Figure 12C).  
This suggests that, like NO, H2S may affect AT2R expression, and thus indirectly 
mitigate the progression of EMT. While subtle, this suggests a novel mechanism by 
which H2S can mediate the progression of EMT, however further studies, potentially 
involving receptor knockdowns, are required to fully characterize the effect of H2S on 
AT2R expression.  
 
Taken together, we propose that H2S exhibits a two-fold modulation of the TGF-β1-
mediated EMT pathway. It is likely that H2S may stimulate the production of inhibitory 
Smad7, thereby degrading the Smad3 proteins that are necessary for EMT signal 
transduction. Slightly upstream, it is also likely that H2S modulates EMT by subtly 
increasing the expression of AT2R, thereby abrogating the expression of TGF-β1R2 
(Figure 13). 
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Figure 13. Proposed mechanism of action of H2S in TGF-β1-mediated EMT 
pathway. TGF-β1 binding to receptor phosphorylates Smad2 and Smad3, which then 
binds to Smad4 and translocate into the nucleus. In the nucleus, it acts as a transcription 
factor to increase the expression of mesenchymal markers, such as vimentin and 
fibronectin, and decrease the expression of epithelial characteristics. We propose that H2S 
acts by increasing AT2R, an upstream inhibitor of the TGF-β1 pathway, and Smad7, a 
negative regulator of EMT. This leads to the decreased expression of TGF-β1R2 and 
Smad3, and ultimately, the attenuation of fibrosis. 
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4.7 Conclusions and future implications  
We demonstrate, for the first time, the effects of H2S on renal function following the 
relief of urinary obstruction by employing the UUO-R model. H2S supplementation 
during urinary obstruction and following decompression can accelerate the recovery of 
renal function, as demonstrated by reduction of serum creatinine and FENa. Furthermore, 
H2S can modulate urinary protein levels, which suggests that it is able to diminish renal 
injury due to hypertension and hyperfiltration.  We propose that H2S mediates 
hypertension by acting on the AT2R, however, future studies should explore the exact 
mechanism and interaction. Additionally, we have demonstrated that H2S 
supplementation can help preserve renal architecture following UUO, likely due to its 
ability to increase tubular regeneration and proliferation. This could have also contributed 
to the reduction of proteinuria. Supplemental H2S also mitigated renal apoptosis, 
inflammation, and fibrosis associated with UUO. Interestingly, we found an increased 
proportion of M2 macrophages in renal tissue following H2S treatment, which suggests 
that H2S may have contributed to the resolution of inflammation by driving macrophages 
towards the reparative, anti-inflammatory M2 phenotype.  However, the exact 
mechanism by which H2S regulates macrophage polarization is unknown. We 
recommend that future studies examine the relationship between the anti-inflammatory 
properties of H2S and its ability to drive macrophages towards the M2 subtype.  As we 
observed a recovery in the histopathological markers of renal injury on POD 30, but did 
not observe a statistically significant difference in renal function following treatment with 
GYY4137, future studies should explore the long-term effects of GYY4137 on renal 
function following UUO-R. It is possible that GYY4137 treatment is able to impede the 
progression of AKI to CKD.  
 
To elucidate potential mechanisms by which H2S ameliorates renal fibrosis, we employed 
an in vitro model of TGF-β1-mediated EMT in NRK 52E cells. We found that H2S 
supplementation attenuated the progression of EMT by upregulating inhibitory Smad7, 
which likely contributed to the degradation of signal transducer Smad3. Furthermore, 
H2S may potentially upregulate AT2R, an upstream regulator of the TGF-β1-mediated 
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EMT pathway, which ultimately led to the downregulation of TGF-β1R2, however, 
futures studies should determine the exact mechanism by with H2S mediates AT2R 
expression.  
 
Prolonged urinary obstruction can lead to irreversible renal injury and renal dysfunction. 
While various surgical treatments are available to remove the obstruction, recovery of 
renal function following decompression may not be complete. Currently, 
pharmacological interventions are typically used to mediate the severe flank pain 
associated with urinary obstruction, however, they do not mitigate the accumulation of 
renal injury. As the severity of renal injury is a strong determinant in the recovery of 
renal function, this suggests that reducing renal injury during urinary obstruction could 
lead to improved renal function following decompression. Our study has important 
clinical implications as we demonstrated that H2S treatment in urinary obstruction not 
only leads to a faster recovery of renal function, but it also mitigates renal injury and 
fibrosis. As such, H2S could be potentially be a therapeutic strategy in improving patient 
outcomes and renal function following urinary obstruction. As partial obstructions are 
more commonly seen in clinic, we suggest that future studies determine the effect of H2S 
on renal function following the relief of a partial obstruction. Furthermore, there has been 
a recent surge in the production of bioavailable H2S donors, such as ATB-346 (Wallace 
et al. 2017). To determine the role of H2S in renal recovery following urinary obstruction 
in a clinical setting, ATB-346 would be a potential candidate for future clinical trials 
involving patients with urinary obstruction.  
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